Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.45 |
| ▸ | DCTPP1 | Q9H773 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30879415 | 0.92 | DCTPP1 (0.45) | DCTPP1MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL20401101 | 0.88 | GLS (0.57) | GLSDCTPP1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL24996626 | 0.83 | QPCT (0.46) | DCTPP1KMT2AMEN1NPBWR1 | |
| SCHEMBL30879444 | 0.83 | QPCT (0.46) | DCTPP1KMT2AMEN1NPBWR1 | |
| SCHEMBL11002083 | 0.77 | GLS (0.67) | GLSMAPTKMT2AMEN1CNR1 | |
| SCHEMBL3376313 | 0.77 | GLS (0.54) | GLSMAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4231911 | 0.76 | ALDH1A1 (0.54) | MAPTKMT2AMEN1CRHBPCRHR2 | |
| SCHEMBL31357438 | 0.75 | HTR2A (0.46) | DCTPP1KMT2AMEN1NPBWR1 | |
| SCHEMBL24997051 | 0.75 | HTR2A (0.46) | DCTPP1KMT2AMEN1NPBWR1 | |
| SCHEMBL28899217 | 0.74 | MAPT (0.52) | MAPTSMN1; SMN2KMT2AMEN1NPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391931-A1 | TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-11-28 | — | — | US | disclosed |
| CN-117980309-A | Tricyclic fused pyrimidine compounds useful as HER2 inhibitors | 百时美施贵宝公司 | 2024-05-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391931-A1 | TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS | ERBB2, ERBB3, EGFR | GLS 589/4885DCTPP1 328/4885MAPT 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.